卵巢浆液性囊腺癌组织中prostasin基因的表达及意义

Expression of prostasin in ovarian serous cystadenocarinema tissues and its significances

目的:研究卵巢浆液性囊腺癌组织中prostasin基因的表达,探讨prostasin基因在卵巢浆液性囊腺癌发生和发展中的意义。方法:应用逆转录聚合酶链反应(RT-PCR)法检测10例卵巢浆液性囊腺癌、10例卵巢浆液性囊腺瘤及10例正常卵巢组织中prostasin mRNA的表达量。应用免疫组织化学方法检测prostasin蛋白在60例卵巢浆液性囊腺癌、24例卵巢浆液性囊腺瘤及24例正常卵巢组织中的表达率。结果:prostasinmRNA在卵巢浆液性囊腺癌组织中表达量显著增高(0.415±0.177),与正常卵巢组(0.192±0.128)及卵巢浆液性囊腺瘤组(0.237±0.232)比较,差异均有显著性(P<0.05)。prostasin蛋白主要在细胞质中表达,在卵巢浆液性囊腺癌组的阳性表达率(65.0%)明显高于正常卵巢组(12.5%)及卵巢浆液性囊腺瘤组(25.0%)(P<0.01);卵巢浆液性囊腺癌病理分级越高、临床分期越晚组织中prostasin蛋白表达率越高(P<0.05)。结论:prostasin基因在卵巢癌发生和发展中起促进作用。

Objective To study the expression of prostasin in ovarian serous cystadenocarcinoma tissues and disscuss the significances of prostasin gene in the occurrence and development of ovarican carcinoma. Methods RT-PCR method was used to investigate the expressions of prostasin mRNA in tissue samples of 10 ovarian serous cystadenocarcinoma, 10 ovarian serous cystadenoma and 10 normal ovary. The expressions of prostasin protein in 60 ovarian serous eystadenocareinoma, 24 ovarian serous cystadenoma and 24 normol ovarian tissues were detected by immunohistochemistry. Results The level of prostasin mRNA expression in ovarian serous cystadenoearcinoma tissues （0.415±0.177） was significantly higher than those in normal ovarian tissues （0.192±0.128） and ovarian serous eystadenoma tissues （0.237±0.232）（P〈0.05）. The expression of prostasin protein was mostly located in cytoplasm; the positive expression rate of prostasin protein in ovarian serous eystadenocarcinoma group was 65.0%, which was significantly higher than those in normal ovarian group （12.5%） and ovarian serous cystadenorna group （25.0%） （P〈0.01）; there was correlation between the expression intensity of prostasin protein and pathological grading and clinical stages; the higher clinical stage and the worse differentiation of ovarian serous cystadenocarcinoma, the stronger positive expression of prostasin protein. Conclusion Prostasin gene plays a promotion effect on the course of occurrence and development of ovarian carcinoma.